ALNYLAM PHARMACEUTICALS, INC. (ALNY) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001178670 · SEC filings checked Oct 17, 2026
Next report
Oct 29, 2026
Estimated from reporting history (91-day cycle, SEC 8-K item 2.02 results filings). Not confirmed.
Last close
$231.83
Polygon.io daily close, Oct 16, 2026. End of day, not live.
Trailing diluted EPS
—
Needs four consecutive reported quarters.
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 30, 2026 | $1.29B | $164.5M | $1.21 | Filing |
| Mar 31, 2026 | Apr 30, 2026 | Announced; figures arrive with the 10-Q | $206.0M | — | Filing |
| Dec 31, 2025 | Jan 12, 2026 | Announced; figures arrive with the 10-Q | $153.1M | — | Filing |
| Sep 30, 2025 | Oct 30, 2025 | $1.25B | $251.1M | $1.84 | Filing |
| Jun 30, 2025 | Jul 31, 2025 | $773.7M | $-72.2M | $-0.55 | Filing |
| Mar 31, 2025 | May 1, 2025 | Announced; figures arrive with the 10-Q | $-18.3M | — | Filing |
| Dec 31, 2024 | Jan 13, 2025 | $593.2M | $-83.8M | $-0.66 | Filing |
| Sep 30, 2024 | Oct 31, 2024 | $500.9M | $-111.6M | $-0.87 | Filing |
What would ALNYLAM PHARMACEUTICALS, INC. have to report for its valuation to change?
Four consecutive reported quarters of diluted EPS are not available in SEC filings. The model is not shown rather than filled with assumptions.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.